摘要
目的 分析糖皮质激素联合复方异丙托溴铵治疗老年慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床效果及对肺功能指标的影响。方法 选取我院2018年10月至2021年10月收治的80例老年AECOPD患者作为研究对象,根据治疗方法的不同将其分为对照组(40例,常规治疗)和试验组(40例,常规治疗+布地奈德+复方异丙托溴铵)。比较两组患者的治疗效果。结果 试验组的治疗总有效率为97.50%,高于对照组的75.00%(P<0.05)。治疗后,试验组的各项症状(喘息、咳嗽、气促)积分低于对照组(P<0.05)。治疗后,试验组的PEF、FVC、FEV1、Cst、OI均高于对照组(P<0.05)。治疗后,两组的SOD水平均升高,MDA、MCP-4、HIF-1α、IL-17水平均降低,且试验组优于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 糖皮质激素联合复方异丙托溴铵治疗老年AECOPD患者的临床效果显著,能够缓解患者的临床症状,改善肺功能,减轻机体应激及炎症反应,且安全性较高,利于促进患者康复。
Objective To analyze the clinical effect of glucocorticoid combined with compound ipratropium bromide in the treatment of elderly patients with opium bromide for acute exacerbation of chronic obstructive pulmonary disease(AECOPD) and its effect on pulmonary function indexes. Methods A total of 80 elderly AECOPD patients admitted in our hospital from October 2018 to October 2021 were selected as the research objects, and the patients were divided into control group(40 cases, conventional treatment) and experimental group(40 cases, conventional treatment + budesonide+ compound ipratropium bromide) according to different treatment methods. The therapeutic effects of the two groups of patients were compared. Results The total effective rate of treatment in the experimental group was 97.50%, which was higher than 75.00% in the control group(P<0.05). After treatment, the scores of various symptoms(wheezing, cough,shortness of breath) in the experimental group were lower than those in the control group(P<0.05). After treatment, the PEF, FVC, FEV1, Cst and OI in the experimental group were higher than those in the control group(P <0.05). After treatment, the level of SOD in both groups increased, and the levels of MDA, MCP-4, HIF-1α, and IL-17 decreased,and those in the experimental group were better than the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P >0.05). Conclusion Glucocorticoid combined with compound ipratropium bromide in the treatment of elderly patients with AECOPD has a significant clinical effect, it can relieve the clinical symptoms of patients, improve lung function, reduce the body’s stress and inflammatory response, and has higher safety, which is conducive to promoting the recovery of patients.
作者
刘妍
张颖
LIU Yan;ZHANG Ying(Respiratory and Critical Care Medicine Department,Xuzhou No.1 People's Hospital,Xuzhou 221000,China)
出处
《临床医学研究与实践》
2022年第10期49-53,共5页
Clinical Research and Practice
关键词
慢性阻塞性肺疾病急性加重期
糖皮质激素
复方异丙托溴铵
肺功能
acute exacerbation of chronic obstructive pulmonary disease
glucocorticoid
compound ipratropium bromide
pulmonary function
作者简介
刘妍(1987-),女,汉族,江苏徐州人,主治医师,硕士。研究方向:慢性阻塞性肺疾病的诊治。;通讯作者:张颖,E-mail:zhangying-lux@163.com。
